Sioux Falls, SD, September 13, 2012 --(PR.com
)-- pharmaCline® is a pharmaceutical company with targeted therapies for unmet needs in life sciences. The Company is currently in a Private Placement round in support of key product launches.
The pharmaCline Wound Care Division develops and manufactures game changing topical over-the-counter (OTC) first aid antibiotic ointments as well as future Rx solutions. Today the company announced that a poster highlighting a powerful research use of its award winning technology will be presented at the Symposium for the Advancement of Wound Care on September 13th in Baltimore, Maryland.
The poster entitled, “Multi-case Human Field Studies of Diabetic Foot Injuries Treated with Tetracycline delivered by SSPT™: A Novel Delivery System Yields Effective Results” is authored by Dr. Christopher Ayo Otiko, DPM, and features three unique clinical case studies.
“In all three patient case studies the rate of wound closure increased, infection was eradicated and the patients’ lives were dramatically improved,” said Dr. Otiko, DPM.
Use of a proven and well-tolerated legacy antibiotic (tetracycline) in a novel SSPT delivery system appears to restore the original efficacy of the active pharmaceutical ingredient, even against resistant organisms. This discovery will enable new and more effective prescription therapeutic regimens for the most challenging infected wounds. Use of this therapy will enable higher confidence among caregivers for the prevention of Gram-positive and Gram-negative topical pathogens with a single ointment. These results may also facilitate new options for patients who are allergic to known antibiotic ointments having multiple active pharmaceutical agents.
Diabecline® first aid antibiotic ointment is an award winning, hypoallergenic antimicrobial ointment formulated with the maximum strength of tetracycline (3%) available without a prescription. The product uses a unique carrier technology, Site Specific Penetration Technology (SSPTTM) that ensures rapid transport of the antibiotic through the bacterial cell membrane, leading to rapid killing and the establishment of a zone of protection surrounding the wound. pharmaCline is developing a prescription formulation based on this product. The prescription product is scheduled for availability in 2015.
For more information about pharmaCline please visit www.pharmacline.com.
For more information about the Symposium for the Advancement of Wound Care Fall 2012 please visit http://fall.sawc.net/.
pharmaCline is a pharmaceutical company providing solutions in several areas of clinical concern across various medical specialties. Within its Wound Care Division, pharmaCline has developed a proprietary drug delivery technology and award winning product line of topical hypoallergenic antimicrobial drugs. With already listed FDA formulations, the Company has developed a new generation of antimicrobial agents exhibiting high efficacy in humans. Through its “Embrace Healing” campaign, pharmaCline is active in promoting better awareness of wound care basics. The Company is licensed as a drug distributor by the South Dakota Board of Pharmacy. pharmaCline is a member of the U.S. Health and Human Services Partnership for Patients and other life sciences organizations.
Lana McCoy, Executive Marketing Coordinator
2329 N. Career Avenue, Suite 243
Sioux Falls, SD 57107